Objective. Rheumatoid arthritis (RA) is characterized by the activation of B cells that produce anticitrullinated protein antibodies (ACPAs) and rheumatoid factors (RFs), but the mechanisms by which tolerance is broken in these B cells remain incompletely understood. We undertook this study to investigate whether ACPA+ and RF+ B cells break tolerance through distinct molecular mechanisms.
1
Objective. Rheumatoid arthritis (RA) is characterized by the activation of B cells that produce anticitrullinated protein antibodies (ACPAs) and rheumatoid factors (RFs), but the mechanisms by which tolerance is broken in these B cells remain incompletely understood. We undertook this study to investigate whether ACPA+ and RF+ B cells break tolerance through distinct molecular mechanisms.
Methods. We developed antigen-tetramers to isolate ACPA+ and RF+ B cells and performed single-cell RNA sequencing on 2,349 B cells from 6 RA patients and 1 healthy donor to analyze their immunoglobulin repertoires and transcriptional programs. Prominent immunoglobulins were expressed as monoclonal antibodies and tested for autoantigen reactivity.
Results. ACPA+ and RF+ B cells were enriched in the peripheral blood of RA patients relative to healthy controls. Characterization of patient-derived monoclonal antibodies confirmed ACPA and RF targeting of tetramer-specific B cells at both antigen-inexperienced and affinity-matured B cell stages. ACPA+ B cells used more class-switched isotypes and exhibited more somatic hypermutations relative to RF+ B cells, and these differences were accompanied by down-regulation of CD72 and up-regulation of genes that promote class-switching and T cell-dependent responses. In contrast, RF+ B cells expressed transcriptional programs that stimulate rapid memory reactivation through multiple innate immune pathways. Coexpression analysis revealed that ACPA+ and RF+ B cell-enriched genes belong to distinct transcriptional regulatory networks.
Conclusion. Our findings suggest that ACPA+ and RF+ B cells are imprinted with distinct transcriptional programs, which suggests that these autoantibodies associated with increased inflammation in RA arise from 2 different molecular mechanisms.
Rheumatoid arthritis (RA) is characterized by chronic synovitis and joint destruction. Autoantibodies are a hallmark of RA and include anti-citrullinated protein antibodies (ACPAs) and rheumatoid factors (RFs) (1) . Recent data suggest that ACPA and RF autoantibodies uniquely contribute to systemic inflammation and are associated with increased disease activity scores in RA (2) . Furthermore, B cells, which produce autoantibodies and cytokines and provide T cell help, contribute to pathology as evidenced by the efficacy of B cell-depleting therapies in RA (3) .
B cell activation requires coordination of many cell-extrinsic and -intrinsic factors (1), and our understanding of how B cell tolerance is broken in RA remains limited. B cell activation is regulated by B cell receptor (BCR) signaling and costimulatory signals, and dysregulated signaling events can promote the survival and differentiation of autoreactive B cells that would otherwise be deleted or tolerized. RFs, which can be present in other autoimmune diseases and chronic inflammation states, can also develop following acute microbial infections (4, 5) . RF generation has been recapitulated through challenges with lipopolysaccharide or double-stranded DNA in mice, providing evidence that RF+ B cells become activated in diverse states of inflammation (6, 7) . In contrast, ACPAs are highly specific for RA and promote synovial inflammation and joint destruction in mouse models (8, 9) . Indeed, ACPA+ B cells continuously undergo antigen-driven activation throughout disease, as evidenced by the continual regeneration of ACPA+ plasmablasts in patients (10) . Based on these observations, we reasoned that the development and persistence of RFs and ACPAs may involve differential regulation of B cells at different stages of differentiation and may arise through the loss of tolerance mediated by distinct mechanisms.
In the present study, we developed antigentetramer staining reagents to isolate RF+ and ACPA+ B cells from seropositive RA patients and used single-cell RNA sequencing (RNA-Seq) to simultaneously recover the paired BCR variable region and the transcriptional profiles of individual B cells. By using a subset of B cells with assessed surface markers and sequenced immunoglobulins, we developed a computational B cell classifier ("BCellNet") that used the single-cell RNA-Seq profile to organize B cells by subtype and characterize the primary, secondary, and antibody-producing stages of B cell differentiation. We applied these new methods to RA and identified distinct activation programs that distinguish RF+ B cell responses from ACPA+ B cell responses. Our findings suggest that tolerance mediated by 2 different molecular mechanisms must be broken to activate ACPA+ and RF+ B cells to produce autoantibodies and promote synovitis in RA.
PATIENTS AND METHODS
Study design. All samples were collected after obtaining informed consent and according to human subject protocols approved by the Investigational Review Board at Stanford University (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40578/abstract). Peripheral blood was obtained from 6 individuals with RA who met the American College of Rheumatology 1987 revised classification criteria (11), were seropositive for RF and/or anti-cyclic citrullinated peptide (anti-CCP), and did not receive B cell-depleting therapy. Five age-matched healthy donors who were negative for HIV and tuberculosis were recruited from the Stanford Blood Center.
Autoreactive B cell isolation. RF tetramers were prepared as described in Supplementary Methods, http://onlinelibrary. wiley.com/doi/10.1002/art.40578/abstract. Fourteen citrullinated peptides (400 lM) of highly prevalent citrullinated protein antigens (12) were selected for citrullinated protein tetramer preparation as described in Supplementary Methods. Live CD3ÀCD14ÀCD19+ B cells were sorted using a FACSAria II flow cytometer (Becton Dickinson) at a single-cell purity of >99%. B cells were considered ACPA+RFÀ or RF+ACPAÀ if they stained double positive for the autoantigen of interest and double negative for the other tetramerized antigen.
Library preparation and next-generation sequencing. Template-switching reverse transcription of messenger RNA was primed using the STRT-oligo (13) , and complementary DNAs (cDNAs) were barcoded using template-switched oligos containing cell and molecular identifiers (see Supplementary  Table 2 , http://onlinelibrary.wiley.com/doi/10.1002/art.40578/ abstract). Barcoded cDNA libraries were pooled and amplified using PCR1-FWD and PCR1-REV primers and then sonicated. We purified 5 0 fragments of cDNA molecules using MyOne C1 Streptavidin Dynabeads (Life Technologies) and uncoupled them by restriction digestion. Libraries were constructed using TruSeq-V2 kits (Illumina) and sequenced using a HiSeq 2000 Sequencing System (2 9 100 bp read length; Illumina). Details are available in Supplementary Methods, http:// onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract.
Single-cell RNA-Seq pipeline. Custom R scripts extracted cell and molecule barcodes from raw sequencing reads. Reads were aligned to the human genome (Genome Reference Consortium Human Build 38) (14) using Bowtie2 software (version 2.1.0) (15) . Duplicate reads generated by polymerase chain reaction were removed, and final expression was calculated using RSEM software (version 1.2.25) (16) . The BCellNet subtype classification was trained as described in Supplementary Methods (http://onlinelibrary.wiley.com/doi/10.1002/ art.40578/abstract), allowing us to estimate a classification function that provided the most likely cell type for any cell with a single-cell RNA-Seq profile. De novo assembly of immunoglobulin V H and V L regions, classification of germline V, D, and J regions, and identification of third complementarity-determining region (CDR3) clusters were performed as described in Supplementary Methods.
Recombinant monoclonal antibody testing. A preliminary list of candidate antibodies was first generated from autoreactive CDR3 clusters. The top V H -V L pairings from each CDR3 cluster with complete V-region sequence reconstitution were expressed as human IgG1 antibodies with IgL2 or IgK light chains (LakePharma). RF reactivity was determined by generating F(ab 0 ) 2 fragments and probing plates coated with Human IgG, Fc fragment (Jackson ImmunoResearch). CCP binding was determined using a CCP3 enzyme-linked immunosorbent assay (ELISA; Inova Diagnostics). The threshold for positivity was 3 SD above the mean of negative control monoclonal antibodies. Autoantigen microarrays were printed and probed as previously described (9) . Details are available in Supplementary Methods, http://onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract.
Differential expression testing. We tested differential expression through a series of linear models including a subsetstratified model, which accounts for the probability of cells belonging to the plasmablast (antibody-secreting cell [ASC]), double-negative (DN), memory, and naive subtypes, and a global model, which does not account for subtype. Further explanation of the 2 models is in Supplementary Methods, http:// onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract.
Both models were fit in MAST (17) version 0.933 using a 2-step procedure to select genes that showed consistent differential expression across patients. Genes were considered to be differentially expressed if they 1) were marginally differentially expressed at a false discovery rate (FDR) of 10% and 2) had a standardized effect size of >2. The standardized effect size selects genes most likely to substantially affect transcription in the population of RA patients. Both models also returned a partial residual, which is the logarithm of expression after correction for nuisance factors. Gene functional categories were defined by organizing the differentially expressed genes (DEGs) and 33 
RESULTS
Elevation of naive, memory, and antibody-secreting autoreactive B cells in blood of RA patients. In this study, we sampled blood B cells from seropositive RA patients using flow cytometry to examine the frequency of ACPA+ and RF+ B cells as well as to isolate these cells for singlecell RNA-Seq analysis ( Figure 1A ). To isolate RF+ and ACPA+ B cells, biotinylated human IgG Fc as well as 14 citrullinated peptides previously demonstrated to be targeted by RA ACPAs were individually coupled to 2 sets of streptavidin-bound fluorophores ( Figure 1B ). Autoantigen labeling with dual fluorophores was previously demonstrated to reduce the false-positive detection of fluorophore-reactive B cells, and tetramerization enabled the detection of B cells expressing BCRs with moderate affinity for autoantigen epitopes (10, 18) . Analysis of B cell frequencies revealed that RF+ and ACPA+ cells were virtually undetectable in healthy controls (<0.01%) and rare in blood from RA patients, comprising on average 0.25% and 0.14%, respectively, of sampled B cells ( Figure 1C ). This small enrichment of RF+ and ACPA+ cells in RA patients was significant compared to healthy controls. While the frequency of RF+ and ACPA+ B cell subsets varied between patients, autoreactive B cells from the CD27À (naive, nonaffinity matured, and DN memory) and CD27+ (classical memory) compartments were present in all individuals, consistent with previous observations of defective central and peripheral tolerance in RA (19, 20) . The presence of RF+ and ACPA+ ASCs in blood of RA patients reveals that they have active ongoing humoral autoimmunity.
We then performed single-cell RNA-Seq on sorted ACPA+, RF+, and tetramer-negative B cells from RA patients and 1 healthy donor, using a modified STRT-Seq method that enables single molecule quantification and computational reconstitution of the paired BCR for each B cell ( Figure 1A ; also see Supplementary Figure 1 , http://onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract). The population of tetramer-negative cells provides a baseline to compare characteristics of the autoreactive populations. After aligning and deduplicating reads, we recovered an average of 4.8 9 10
4 molecules per cell with no substantial differences between experimental groups (see Supplementary Figure 2 , http://onlinelibrary.wiley. com/doi/10.1002/art.40578/abstract).
BCellNet predicts peripheral B cell subsets using single-cell RNA-Seq profiles. To evaluate the contribution of various B cell subsets to RA pathology, we organized B cells by subtype using a B cell transcriptomic classifier we developed, termed BCellNet. Predicting subtype with this transcriptomic classification scheme allows us to consider a continuum of differentiation states (21) and assign a subset probability score for each cell, improving upon the quantized subset identifications available in flow cytometric gating. In total, 159 genes (<2.5%) served as predictors (see Supplementary Table 3 , http://onlinelibrary.wiley. com/doi/10.1002/art.40578/abstract). Some, such as MS4A1 and TNFRSF13B, were previously described in bulk-level studies (22) , while others, such as SEC61G and EIF5A, were novel (see Supplementary Figure 3 , http:// onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract).
Applying BCellNet to heterogeneous B cells isolated from RA samples demonstrated positive correlations between subtype fractions assessed by flow cytometry and the classifier (Spearman's q = 0.56-0.89), indicating that the classifier recapitulates flow cytometry-identified populations while also parsing subtype-dependent gene effects (see Supplementary Figure 4 , http://onlinelibrary.wiley. com/doi/10.1002/art.40578/abstract). There were certain discrepancies between the flow fractions and classifier fractions, likely due to sampling variability in the flow sorting and classification error from BCellNet. However, we do not believe that these discrepancies significantly altered B cell subtype classification (see Supplementary Methods, http://onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract). In light of this, rather than using quantized assignments to the most likely subtype, we used the continuously valued posterior probabilities of subtype membership as stratifying covariates for subsequent analysis (see Supplementary  Table 4 , http://onlinelibrary.wiley.com/doi/10.1002/art.40578/ abstract).
We observed a general correlation between serologic autoantibody levels and the recovery of ACPA+ and RF+ B cells, despite minor variances in the number of cells sorted due to stochastic selection during fluorescence- 26c370  48c208  48c225  48c241  48c243  48c297  48c312  59c226  59c271  59c367  26c300  26c375  26c395  48c212  48c321  48c285  48c289  26c384  59c219  72c323  72c379  72c392  48c288  48c280  48c255  48c227  26c288  26c363  72c361  26c237  26a344  26a369  HD5a289  26a389  04a241 Figure 2B ; also see Supplementary Figure 6 , http://onlinelibrary.wiley.com/ doi/10.1002/art.40578/abstract). This represented the most stringent threshold that preserved cluster membership among cells that exhibit identical germline genes and CDR3 lengths and that therefore putatively derive from the same progenitor (23) (see Supplementary Table 6 , http:// onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract).
To determine if the size of the CDR3 clusters can measure the magnitude of convergent evolution, we compared the number of cells per tetramer group in each CDR3 cluster to calculate the cluster multiplicity. If each cell from a tetramer group clustered separately, then the multiplicity would be 1, while if all N cells were in a single cluster, the multiplicity would be N. ACPA+ B cell multiplicities were significantly larger than tetramer-negative B cell multiplicities in 2 of 4 patients (multiplicity differences 1.3 and 0.3 cells/cluster; P < 0.002 under hypergeometric sampling) and significantly larger than RF+ B cell multiplicities in 1 of 3 patients (multiplicity difference 0.17 cells/cluster; P < 0.04). No significant differences were observed between RF+ B cell multiplicities and tetramer-negative B cell multiplicities. Hence, the elevated frequency of CDR3 convergence suggests that ACPA+ B cells undergo extensive affinity maturation relative to tetramer-negative and RF+ B cell populations.
We then expressed 42 representative RF and ACPA BCRs from the most prominent V H -V L pairings and CDR3 clusters as recombinant monoclonal antibodies to identify their autoantigen targets and examine whether autoreactivity is present in antigen-inexperienced and -experienced B cell stages (Figures 2A and B ; also see Supplementary Table 7 , http://onlinelibrary.wiley. com/doi/10.1002/art.40578/abstract). Eleven of the 12 antibodies cloned from RF-sorted cells bound to human IgG Fc, while only 1 of the 30 antibodies from ACPAsorted cells bound to IgG Fc, and none of the antibodies from tetramer-negative B cells bound to IgG Fc (Figure 2C) . We also found that 13 of the 30 monoclonal antibodies from citrullinated antigen-sorted cells bound to CCP3, a citrullinated peptide mimic used to diagnose RA. ) for each antigen specificity. B, Class-switch rates for antigen-experienced ACPA+, RF+, and tetramer-negative (TetÀ) B cells in rheumatoid arthritis patients, adjusting for subset differences and patient variability using a generalized linear mixed model. C, Somatic mutation rates for antigen-experienced ACPA+, RF+, and tetramer-negative B cells by subtype. D, Somatic mutation rates for immunoglobulins expressed by ACPA+, RF+, and tetramer-negative B cells, adjusting for subset differences and patientto-patient variability using a linear mixed model. In B and D, values are the mean and 95% confidence interval. In C, values are the mean AE SEM. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. NS = not significant; AA = amino acid.
None of the antibodies from tetramer-negative B cells recognized CCP3, and only 2 of the 12 antibodies from RF-sorted cells bound CCP3 ( Figure 2C ). Using the CCP3 ELISA and a protein microarray coated with >300 RA autoantigens, we identified citrullinated antigen hits for 25 of the 30 antibodies from citrullinated antigensorted cells ( Figure 2D ). We do note that several antibodies cloned from ACPA+ B cells were cross-reactive with noncitrullinated antigens, consistent with previous reports (9) . This confirms that the RF-tetramer and ACPA-tetramer reagents enabled isolation of RF+ and ACPA+ B cells. Notably, RF+ and ACPA+ B cells are in all subsets, including non-affinity matured cells, implicating dysfunctional central and peripheral tolerance in RA.
RF+ and ACPA+ B cells differ in class-switch and somatic mutation frequencies. We next investigated whether the duration of affinity maturation differs between ACPA+ and RF+ B cells, as measured through class-switch recombination (CSR) rates and accumulated somatic mutations on the BCR. Because CSR and mutation rates vary between subtypes, which themselves vary by specificity, we used a mixed-effects logistic regression to measure the unique effect of antigen on CSR and mutation rates adjusted for subtype. We found that ACPA+ B cells had >3.8-fold greater odds of being class-switched than tetramer-negative B cells and 3. and B). We also found that RF+ B cells were 3% less mutated from germline than tetramer-negative B cells, while ACPA+ B cells had 1% higher mutation rates than tetramer-negative B cells, although the difference was not significant (Figures 3C and D) . Thus, ACPA+ B cells undergo more isotype class-switching, have higher mutation rates, and show evidence of increased CDR3 convergence, while RF+ B cells tend to use unswitched isotypes and have fewer mutations.
Functional differential regulation in the primary and secondary RF+ and ACPA+ B cell responses. To elucidate the transcriptional profiles underlying the BCR differences between RF+ and ACPA+ B cell responses, we applied a hurdle model to identify 454 DEGs between RF+, ACPA+, and tetramer-negative B cell populations for all patients in global (i.e., regressing out the effect of subset on gene expression) and subset-stratified comparisons ( Figure 4A ; also see Supplementary Tables 8 and 9 KMT2D  JAK3  CD84  EGF  JAM2  GDE1  ITGB2  TNFRSF1B  MEF2C  REL  SELL  FAM129C  HERC3  ASRGL1  SOX5  NAMPT  CYFIP2  BACH1  BACH2  PIGM  DBN1 MSH5  BEND7  HSP90AA1  KMT2D  CD72  TBRG4  CXCR4  FCER2  GNG7  CD320  CCND2  TRAM2 http://onlinelibrary.wiley.com/doi/10.1002/art.40578/abstract). Performing both global and subset-stratified analyses allowed us to identify a greater amount of DEGs than would be possible using either method alone. Both gene sets were relevant to identifying autoreactive B cell signatures. To examine the cumulative functional impact of the DEGs, we organized DEGs into modules based upon previously published literature. The partial residual for each gene, which represents residual expression attributable to antigen specificity, was used to calculate a module score for ACPA+, RF+, and tetramer-negative cells for each subtype (see Supplementary Figure 7 , http://onlinelibrary. wiley.com/doi/10.1002/art.40578/abstract), pinpointing the developmental stage(s) at which differential autoimmune regulation occurs. The most significantly different modules were concentrated within the naive and memory compartments ( Figures 4B and C) . ACPA+ B cell primary responses initiate classswitch programs and down-regulate CD72. In the naive ACPA+ B cell population, module scores for antibody response and B cell activation were elevated relative to the RF+ and tetramer-negative naive B cell populations ( Figures 5A and B) . Within these modules, the genes MSH5, JAK3, and EXOC4, which all promote antibody class-switched responses (24-26), were highly elevated in the naive ACPA+ B cell compartment and sustained in memory ACPA+ B cells ( Figure 5C ). Additionally, CD72, which inhibits the differentiation of resting B cells, was down-regulated in naive and memory ACPA+ populations but not in RF+ cells (27) . In the B cell activation module, we detected naive ACPA+ B cell elevation of the adhesion molecule genes CD84, JAM2, and ITGB2, which prolong B cell-T cell interactions and thereby promote affinity maturation (28, 29) (Figure 5D ). Taken together, these signatures suggest that ACPA+ B cell responses are programmed for class-switching through T cell help and facilitated by CD72 down-regulation in the naive stage.
RF+ B cells express transcriptional programs associated with IgM responses and rapid recall responses. Within the B cell activation module, the transcription factor SOX11, which promotes highly proliferative IgM responses and suppresses germinal center transcription factor BCL6, and DBN1, a SOX11-regulated gene, were elevated in memory RF+ B cells relative to memory ACPA+ B cells and tetramer-negative B cells (30, 31) ( Figure 5D ). The transcriptional regulator BACH2 was also significantly up-regulated in memory RF+ B cells relative to memory ACPA+ B cells, which is a feature of unswitched B cell responses (32, 33) (Figure 5D ). The selective up-regulation of SOX11 and BACH2 in memory RF+ B cells provides an explanation for their low classswitch and mutation rates.
Differences in B cell costimulation drive ACPA generation and RF versatility to multiple innate activation pathways. Innate immune mediators provide costimulatory signals that can augment B cell responses (34) . In the memory compartment, RF+ and ACPA+ cells exhibited differentially expressed subsets of genes despite not having higher average module scores relative to tetramernegative B cells (Figures 6A and B) . RF+ memory B cells exhibited altered expression of signature genes involved in myeloid differentiation factor 88 (MyD88) signaling (LRRFIP1), interferon (IFN) signaling (IFI6, PSMB10), and DNAX-activation protein 12 (DAP-12) signaling (SIGLEC14), none of which were enriched in ACPA+ memory B cells ( Figure 6B ). In contrast, ACPA+ memory B cells showed coordinated up-regulation of positive regulators of NF-jB signaling (REL and HSP90AA1) (Figure 6B) , which is critical for promoting germinal center responses and survival (35) .
Distinct antibody response and innate immune transcriptional regulatory networks characterize ACPA+ and RF+ B cells. We analyzed single-cell gene coexpression to identify transcriptional regulatory networks within genes differentially expressed by ACPA+ and RF+ B cells and to provide insights into the mechanisms underlying the loss of tolerance in ACPA+ B cells as compared to RF+ B cells (see Supplementary Table 10 , http://online library.wiley.com/doi/10.1002/art.40578/abstract). In both the primary response and memory compartments, ACPA+ B cells coexpressed MSH5, CD84, and JAK3 ( Figures 6C  and D) , revealing a coregulated transcriptional network specific to ACPA development. We also investigated whether upstream effectors of JAK3 signaling were coexpressed with JAK3. IL21R, which receives signals from follicular helper T cells, was coexpressed with the MSH5/ CD84/JAK3 network in ACPA+ memory B cells (36, 37) ( Figure 6D) . Coexpression of these genes suggests that JAK3 links germinal center signals with class-switch functions in both ACPA+ B cell primary and secondary responses. Thus, antigen-experienced ACPA+ B cells exhibit a transcriptional program characterized by a robust germinal center response.
We found evidence that RF+ B cells coexpressed genes belonging to multiple B cell response pathways. The innate immune genes PSMB10, LRRFIP1, IFI6, and SIGLEC14 were all coexpressed, implying that individual memory RF+ B cells exhibit coordinated upregulation of genes ( Figure 6D ). Further, we found that these genes were all significantly coexpressed with PRDM1 and CCND2. The coexpression among these innate immune genes, SOX11, and markers of ASC TMEM181  HSP90AA1  TCL1A  IL17RD  TLR7  PRKRIR  ADAM10  PSMB10  LRRFIP1  HSP90AB1  ARRB2  UBE2V1  SARNP  MEGF9  F5  BPIFB1  TRIM56  REL  VSIG10  SAMD9  TRIM73  MGST3  PTGER4  TXLNG  NKG7  MLLT4  ITGB2  P2RY10  F2RL2  SRP72  PYGL  BRCA2  TNFRSF1B  ARHGEF10  SIGLEC14  IL18RAP  IFI6  MUC5B  UBE2D1  ITGB3BP  GZMH  TNFAIP2  CD2  GZMB 
DISCUSSION
Accumulating clinical evidence implicates a pathogenic role of B cells in RA (3, 38, 39) , and therapeutic modalities that specifically target dysregulated pathways in autoreactive B cell development will be critical for sustained remission. In the present study, we investigated the differential regulation of B cell tolerance in RA using antigen-tetramers to isolate disease-relevant B cells, and we used single-cell RNA-Seq to define RF-and ACPAspecific immunoglobulin usage and transcriptional programs. Our findings demonstrate that ACPA+ and RF+ B cells are imprinted with distinct transcriptional programs, suggesting that different molecular mechanisms mediate the loss of tolerance in ACPA+ B cells versus RF+ B cells.
While self-reactive B cell precursors leak into the periphery at a low frequency in healthy individuals (40) , the nearly exclusive detection of CD27ÀIgM+IgD+ACPA+ B cells and the elevation of CD27ÀIgM+IgD+RF+ B cells in RA patients indicate that ACPA+/RF+ B cell precursors are predominantly deleted in healthy individuals but not in RA patients. This suggests a defect of central tolerance in RA that is likely due to a combination of genetic and environmental factors. Defective regulation through polymorphisms in BCR signaling genes as well as altered receptor editing have been previously reported and may permit the survival of autoreactive immature B cells that are normally removed (41) . Systemic inflammatory mediators can also promote the survival of autoreactive B cells by overwhelming apoptotic or receptor-editing processes (42) . While our data indicate that differential regulation of ACPA+ B cells begins at the naive stage, future studies will be needed to decipher whether this occurs in the bone marrow or in the periphery.
The development of ACPAs appears to stem from multiple defective tolerance mechanisms that fail to restrain ACPA+ B cell activation and from promotion by autoreactive T cell help. In support of this, a study by Makrygiannakis and colleagues demonstrated that citrullinated protein levels are increased in both RA and non-RA inflamed tissues, yet only RA patients persistently develop ACPAs (43) . We found that CD72, an inhibitory coreceptor, was down-regulated in naive ACPA+ B cells relative to RF+ and tetramer-negative B cells. This may enable transduction of activating B cell signals that override tolerogenic signals received by ACPA+ B cells (44) . In addition, expression of the coreceptor CD21 was down-regulated between naive ACPA+ and tetramer-negative B cells, although this effect was not significant in our study.
Once activated, ACPA+ B cells undergo extensive affinity maturation as evidenced by high mutation rates, class-switching rates, and CDR convergence that are associated with expression of robust transcriptional programs reminiscent of those in germinal centers. The elevation of JAK3 in ACPA+ B cells suggests dependence on the IL21R/JAK3 pathways for ACPA production and provides a potential explanation for why tofacitinib, which targets JAK3, results in lower remission rates in ACPA+ patients (45) . Further emphasizing the importance of T cell help, we found an up-regulation in genes that prolong B cell-T cell interactions (CD84, JAM2, and ITGB2) and in molecules that promote antibody class-switching (MSH5). While these transcriptional signatures suggest that affinity maturation of ACPA+ B cells occurs in germinal centers, future studies will be necessary to determine whether this occurs in conventional germinal center reactions, through ectopic T cell help, or through other mechanisms.
Identification of shared transcriptional programs for ACPA+ B cells that target diverse citrullinated proteins suggests that exposure to a spectrum of citrullinated proteins rather than to a specific citrullinated epitope drives the ACPA response, consistent with a previous study that examined ACPA formation during relapse (38) . Hence, we propose that differential B cell imprinting, enhanced inflammation, and citrullinated protein availability combinatorially create an environment conducive to ACPA+ B cell activation and autoantibody production.
In contrast to the ACPA+ B cell response, the RF+ B cell response is characterized by transcriptional programs associated with broad innate immune activation, rapid recall responses, and ASC differentiation. Unlike the extensive affinity maturation driving the ACPA response, the RF response is characterized by B cells that express IgM and exhibit lower mutation rates. The bias toward the IgM isotype, which can bind up to 10 IgG molecules in its pentameric form, enables RF responses to aggregate secreted antibodies and immune complexes. The low mutation rates suggest that certain V(D)J combinations may be intrinsically reactive with IgG Fc. While T cell help causes ACPA+ B cells to undergo prolonged affinity maturation, RF+ B cells can differentiate into memory B cells or ASCs with minimal somatic hypermutation.
Our data indicate that RF+ B cells mount rapid secondary responses with costimulation from multiple The etiology of RF production in multiple inflammatory contexts remains an area of active investigation. Given the presence of RF in other inflammatory diseases and its relatively lower specificity for diagnosing RA (4,5), our results suggest that RF could represent a response to resolve antibody-mediated inflammation by facilitating the clearance of antibodies and immune complexes (46) . Thus, RF elevations in RA may represent an expanded pool of naturally occurring B cells for the purpose of engulfing antigen-antibody complexes to enable antigen presentation to T cells. Future studies comparing the gene expression of RF+ B cells between individuals with and those without RA will be important to provide further insights into whether RF in fact results from dysregulated B cell tolerance.
Our findings reveal that ACPA+ and RF+ B cells are imprinted with distinct transcriptional programs at different stages of development, with RF+ B cells characterized by activation of innate immune activation pathways, while ACPA+ B cells are characterized by loss of tolerance in the primary response followed by robust affinity-matured responses. Future studies will further define how ACPA+ and RF+ B cells promote tissue damage in RA, as well as the impact of targeted therapies on ACPA+ and RF+ B cell activation.
